

**REDX PHARMA LIMITED**

**("Redx" or the "Company")**

**Redx Pharma concludes trading on JP Jenkins as of 1 May 2025**

**Alderley Park, UK, 1 April 2025** [Redx Pharma](#) (JPJ:REDX), the clinical-stage, biotechnology company focussed on developing novel, small molecule, targeted therapeutics for fibrotic disease, announces the discontinuation of trade on JP Jenkins, with the final day of trade being 30 April 2025.

Redx Pharma arranged for a matched bargain facility to be provided through JP Jenkins on 1 May 2024, after delisting from AIM and under a one year contract which is now complete. The company's ordinary shares were admitted under the ticker: REDX.

JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis. JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).

The indicative price and transaction history are available on J P Jenkins's website at: [www.jpjenkins.com](http://www.jpjenkins.com) until 30 April 2025.

**For further information, please contact:**

**Redx Pharma Limited**

T: +44 (0)1625 469 918

**UK Headquarters**

Erin Hamid, Interim Head of Communications

[ir@redxpharma.com](mailto:ir@redxpharma.com)

**FTI Consulting**

T: +44 (0)203 727 1000

Simon Conway/ Ciara Martin

### **About Redx Pharma Limited**

Redx Pharma (JPJ: REDX) is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry leading ROCK inhibitor portfolio through the clinic, including zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis and RXC008, a GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease. Additionally, the Company has a Phase 2 precision oncology programme which it intends to partner for further development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to develop differentiated therapeutics against biologically or clinically validated targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.